teva glp-1 Launches First Generic Drug for Obesity Teva launches authorized generic of

99% COA supported RUO CAS 2375614-45-8 Molecular weight 3962.4 g/mol Storage -20C recommended (research-only) Package sizes 1 5 mg vial Description Cagrilintide 5 mg research overview Cagrilintide amylin analogue for metabolic and satiety-pathway research

While GLP-1 agonists have become a staple for weight loss and type 2 diabetes management, those with type 1 diabetes taking these medications off-label should be mindful of possible adverse effects, including hypoglycemia and diabetic ketoacidosis (DKA), a serious complication resulting from a lack of insulin in the body

We shouldnt wait for more adverse events, more contaminated batches or more misled patients before we act

Ensure reliable data